Entera Bio Ltd. (ENTX) Form 8-K — Oct 27, 2026
$ENTXForm 8-KItems 5.02, 7.01, 9.01Filed Oct 27, 2026, 8:00 AM ET0001178913-26-004854Original filing
Entera Bio (ENTX) appointed Dr. Juan Camilo Arjona Ferreira, currently Head of R&D and Chief Medical Officer at Organon, to its Board of Directors effective December 1, 2026, succeeding Haya Taitel, who is stepping down without any disagreement. Dr. Arjona Ferreira brings more than 20 years of clinical development experience in women's health, with prior roles at Myovant, Shionogi and Merck, and will also join the compensation committee.
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.